More than 300 current and former biotech and pharmaceutical executives have signed an open letter criticizing a federal Texas judge over his recent decision to suspend FDA approval of the abortion pill mifepristone.
“We cannot stay quiet. We call for the reversal of this decision to disregard science, and the appropriate restitution of the mandate for the safety and efficacy of medicines for all with the FDA, the agency entrusted to do so in the first place,” the executives wrote in the letter.
